These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24997558)

  • 21. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapies for diabetes management.
    Garg SK
    Diabetes Technol Ther; 2013 Feb; 15 Suppl 1():S126-35. PubMed ID: 23441701
    [No Abstract]   [Full Text] [Related]  

  • 23. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
    Furuta Y; Horiguchi M; Sugaru E; Ono-Kishino M; Otani M; Sakai M; Masui Y; Tsuchida A; Sato Y; Takubo K; Hochigai H; Kimura H; Nakahira H; Nakagawa T; Taiji M
    Diabetes Obes Metab; 2010 May; 12(5):421-30. PubMed ID: 20415690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incretin-based therapy in patients with type 1 diabetes mellitus].
    Miyagawa J; Miuchi M; Namba M
    Nihon Rinsho; 2011 May; 69(5):923-9. PubMed ID: 21595283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
    Wu YJ; Guo X; Li CJ; Li DQ; Zhang J; Yang Y; Kong Y; Guo H; Liu DM; Chen LM
    Metabolism; 2015 Feb; 64(2):226-35. PubMed ID: 25195070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus.
    Yang L; Yuan J; Zhou Z
    Can J Diabetes; 2014 Dec; 38(6):473-9. PubMed ID: 25034244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
    Kripke C
    Am Fam Physician; 2009 Mar; 79(5):372. PubMed ID: 19275065
    [No Abstract]   [Full Text] [Related]  

  • 33. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
    McIntyre HF; Grant P
    Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting type 2 diabetes.
    Schwanstecher C; Schwanstecher M
    Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
    Yilmaz Y; Atug O; Yonal O; Duman D; Ozdogan O; Imeryuz N; Kalayci C
    Med Sci Monit; 2009 Apr; 15(4):HY1-5. PubMed ID: 19333209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.
    Hamasaki H; Yanai H
    Int J Cardiol; 2013 Oct; 168(3):e106. PubMed ID: 23972359
    [No Abstract]   [Full Text] [Related]  

  • 38. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical potential of C-peptide replacement in type 1 diabetes.
    Wahren J; Kallas A; Sima AA
    Diabetes; 2012 Apr; 61(4):761-72. PubMed ID: 22442295
    [No Abstract]   [Full Text] [Related]  

  • 40. Latent autoimmune diabetes in the young.
    Bering B; Devendra D
    Clin Med (Lond); 2009 Feb; 9(1):93; author reply 93-4. PubMed ID: 19271615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.